Design and Synthesis of New Anthranyl Phenylhydraz... - BV FAPESP
Busca avançada
Ano de início
Entree


Design and Synthesis of New Anthranyl Phenylhydrazides: Antileishmanial Activity and Structure-Activity Relationship

Texto completo
Autor(es):
Mostrar menos -
Maquiaveli, Claudia do Carmo ; da Silva, Edson Roberto ; de Jesus, Barbara Hild ; Monteiro, Caio Eduardo Oliveira ; Navarro, Tiago Rodrigues ; Branco, Luiz Octavio Pereira ; dos Santos, Isabela Souza ; Reis, Nanashara Figueiredo ; Portugal, Arieli Bernardo ; Wanderley, Joao Luiz Mendes ; Farias, Andre Borges ; Romeiro, Nelilma Correia ; de Lima, Evanoel Crizanto
Número total de Autores: 13
Tipo de documento: Artigo Científico
Fonte: PHARMACEUTICALS; v. 16, n. 8, p. 10-pg., 2023-08-01.
Resumo

Leishmaniasis is a neglected tropical disease affecting millions of people worldwide. A centenary approach to antimonial-based drugs was first initiated with the synthesis of urea stibamine by Upendranath Brahmachari in 1922. The need for new drug development led to resistance toward antimoniates. New drug development to treat leishmaniasis is urgently needed. In this way, searching for new substances with antileishmanial activity, we synthesized ten anthranyl phenylhydrazide and three quinazolinone derivatives and evaluated them against promastigotes and the intracellular amastigotes of Leishmania amazonensis. Three compounds showed good activity against promastigotes 1b, 1d, and 1g, with IC50 between 1 and 5 mu M. These new phenylhydrazides were tested against Leishmania arginase, but they all failed to inhibit this parasite enzyme, as we have shown in a previous study. To explain the possible mechanism of action, we proposed the enzyme PTR1 as a new target for these compounds based on in silico analysis. In conclusion, the new anthranyl hydrazide derivatives can be a promising scaffold for developing new substances against the protozoa parasite. (AU)

Processo FAPESP: 19/23769-4 - Planejamento racional, síntese e estudo da relação estrutura atividade de inibidores da enzima arginase de Leishmania amazonensis para o desenvolvimento de novos fármacos
Beneficiário:Edson Roberto da Silva
Modalidade de apoio: Auxílio à Pesquisa - Regular